PO001 Association of DNA repair genes with tumor mutational burden and microsatellite instability. Jason Ding. Mountain Lakes High School, Mountain Lakes, NJ.

PO002 Inducing homologous recombination deficiency in uterine serous cancer (USC) using AVB-500, a receptor tyrosine kinase AXL inhibitor. Michael D. Toboni. Washington University, St. Louis, St. Louis, MO.

PO003 Global proteomic profiling of endometrial carcinomas identify prognostic markers. Dawn R. Cochrane. BC Cancer, Vancouver, BC.

PO004 Enhancer-promoter chromatin looping is enriched for endometrial cancer GWAS risk variation and reveals biologically relevant candidate susceptibility genes. Dylan M. Glubb. QIMR Berghofer Medical Research Institute, Brisbane, QLD.

PO005 A comprehensive analysis of the transcriptional effects of progesterone receptor isoforms A and B identifies VEGF, PDGF and STAT3 as therapeutic targets. Kimberly K. Leslie. University of Iowa, Iowa City, IA.

PO006 Multi-tissue transcriptome-wide association study identifies genetic mechanisms underlying endometrial cancer susceptibility. Tracy A. O'Mara. QIMR Berghofer Medical Research Institute, Brisbane, QLD.

PO007 Evaluation of crosstalk between estrogen and Wnt signaling in endometrial cancer. Krystle Osby. University of Utah, Salt Lake City, UT.

PO008 ARID1A prevents H3K27-hyperacetylation at active super-enhancers. Jake J. Reske. Michigan State University, Grand Rapids, MI.

PO009 Increased DACH1 mutation frequency in a Kentucky hospital uterine cancer population. McKayla Riggs. University of Kentucky, Lexington, KY.

PO010 Multi-dimensional biomarker analyses identify pembrolizumab responders in advanced stage, high grade endometrial cancer. Katherine C. Fuh. Washington University School of Medicine, St. Louis, MO.

PO011 Spatial immune cell and transcriptome profiling uncover differential cellular and molecular signatures in primary and metastatic tumor sites in patients with advanced uterine serous cancer. Li Zhang. MD Anderson Cancer Center, Houston, TX.

PO012 Characterization of molecular, phenotypic, and drug sensitivity changes due to estrogen receptor alpha mutations in endometrial cancer. Zannel Blanchard. University of Utah, Salt Lake City, UT.
PO013 SNP rs1982 in the 3’UTR of placenta-specific protein 1 (PLAC1) is associated with endometrial cancer survival. Eric J. Devor. University of Iowa, Iowa City, IA.

PO014 Clinicopathologic evaluation of CTNNB1 gene mutations in high-intermediate risk endometrial cancer. Jennifer G. Haag. University of Colorado Anschutz Medical Campus, Aurora, CO.

PO015 The impact of the tumor immune microenvironment on response to pembrolizumab in patients with microsatellite instability-high endometrial cancer. Jeffrey A. How. the University of Texas MD Anderson Cancer Center, Houston, TX.

PO016 Genomic characterisation of endometrial cancer patient-derived xenografts reveals intratumour heterogeneity. Olga Kondrashova. QIMR Berghofer Medical Research Institute, Brisbane, QLD.

PO017 Correlation of immunohistochemistry with TP53 sequence and clinical outcomes in GOG-086P. Kimberly K. Leslie. University of Iowa, Iowa City, IA.

PO018 PAX8 represents a potential novel therapeutic target in copy number high uterine serous carcinoma. Susan H. Read. University of South Florida, Tampa, FL.

PO019 Identification of differentially expressed genes in primary samples of endometrial hyperplasia and endometrioid endometrial carcinoma responsive to progestin therapy. Craig M. Rush. Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.

PO020 Approval for the proliferative marker Ki-67 as an integrated biomarker for endometrial cancer in NRG study GY011. Megan I. Samuelson. University of Iowa, Iowa City, IA.

PO021 Developing pre-clinical models of uterine leiomyosarcoma. Genevieve Dall. Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.

PO022 Multidimensional longitudinal assessment of patients under treatment for advanced endometrial cancer: A new tool to advance research on human disease. Erik Dvergsten. Inova Schar Cancer Institute, Fairfax, VA.

PO023 Preliminary data on metformin therapy in DICER1-deleted endometrial cancer. Shannon M. Hawkins. Indiana University, Indianapolis, IN.

PO024 Identifying mechanisms of immune evasion in microsatellite instable endometrial cancer mouse models. Brenda Melendez. The University of Texas MD Anderson Cancer Center, Houston, TX.

PO025 Development of patient derived organoid cultures of two advanced stage serous carcinomas of the uterus. Andreea Mihai Newton. University of Iowa Hospitals and Clinics, Iowa City, IA.
PO026 Building the infrastructure required to research novel therapies for 35% of women with endometrial cancer who have rare subtypes. Clare L. Scott. Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.

PO027 Characterization of patient-derived xenograft models of endometrial cancer. Kristina W. Thiel. University of Iowa, Iowa City, IA.

PO028 CD73 sequestering mutant β-catenin at the membrane explains recurrence in CTNNB1 mutant endometrial cancer. Jessica L. Bowser. University of North Carolina School of Medicine, Chapel Hill, NC.

PO029 Oral contraceptive use and postmenopausal sex steroid hormone metabolism. Kara A. Michels. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD.

PO030 Understanding the influence of adiposity on the endometrium using human primary endometrial organoids. Alina R. Murphy. Northwestern University, Chicago, IL.

PO031 Docosahexaenoic acid demonstrates anti-tumorigenic effects in endometrial cancer. Jillian A. O'Donnell. University of North Carolina at Chapel Hill, Chapel Hill, NC.

PO032 Bacterial, archaea and viral transcripts (BAVT) expression in endometrial cancer. Silvana Pedra Nobre. University of Iowa Hospitals and Clinics, Iowa City, IA.

PO033 FGFR2 isoform switching strongly associates with progestin treatment failure in atypical hyperplasia and well-differentiated endometrial cancer. Asmerom Sengal. Queensland University of Technology, Brisbane, Australia.

PO034 Long-term follow-up for a prospective phase II trial of levonorgestrel intrauterine device as non-surgical treatment for complex atypical hyperplasia and early endometrial cancer. Mikayla S. Waters. MD Anderson Cancer Center, Houston, TX.


PO036 Patients with recurrent epithelial endometrial cancers (EEC) and Wnt signaling alterations demonstrated greater clinical benefit when treated with DKN-01 monotherapy. Rebecca Arend. University of Alabama at Birmingham, Birmingham, AL.

PO037 Identifying effective combinations of targeted therapies, using novel pre-clinical models, to improve treatment options for high-grade serous endometrial cancer. Holly E. Barker. The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.

PO038 Preclinical development of SHetA2 for endometrial cancer therapy. Doris M. Benbrook. Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK.
PO039 Combined histone deacetylase and proteasome inhibition in patient-derived endometrial cancer organoid models promotes massive cell death. Jianling Bi. University of Iowa, Iowa City, IA.

PO040 Chemoprevention and regression of estrogen-induced atypical endometrial hyperplasia by oral SHetA2 in a rat model. Vishal Chandra. Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK.

PO041 Everolimus and MK-2206 reverse P4-resistant endometrial hyperplasia in Mig-6 mutant mice. Tae Hoon Kim. Michigan State University College of Human Medicine, Grand Rapids, MI.

PO042 ROR2 is epigenetically regulated in endometrial cancer. Dongli Liu. UNSW, Sydney, Australia.

PO043 Targeting beta-catenin and Wnt signaling in CTNNB1-mutated endometrial cancer. Marisa R. Moroney. University of Colorado, Anschutz School of Medicine, Aurora, CO.

PO044 A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer. Sarah E. Paraghamian. University of North Carolina at Chapel Hill, Chapel Hill, NC.

PO045 Inhibition of GAS6/AXL improves efficacy of HER2 inhibitor trastuzumab in uterine serous cancer. Joan Tankou. Washington University School of Medicine, St. Louis, MO.

PO046 Anti-angiogenic tyrosine kinase inhibitor cediranib is superior to bevacizumab in endometrial cancer due to differential effects on cell cycle regulation. Kristina W. Thiel. University of Iowa, Iowa City, IA.

PO047 AVB-500, a receptor tyrosine kinase AXL inhibitor, improves response to olaparib in uterine serous cancer. Michael D. Toboni. Washington University, St. Louis, St. Louis, MO.

PO048 Inhibition of P300 histone acetyltransferase activity rescues invasive phenotypes of ARID1A-deficient endometrial epithelium. Mike R. Wilson. Michigan State University, Grand Rapids, MI.

PO049 Compartment-specific profiling for evaluation of disrupted signaling in early stage, low-grade endometrial cancer. Qian Zhang. UT MD Anderson Cancer Center, Houston, TX.